J&J lands Tremfya one-two punch in IBD with first ulcerative colitis win and long-term Crohn’s datanews2022-02-18T12:52:34+00:00February 18th, 2022|Fierce Pharma|
Fierce Pharma Asia—Lilly, Innovent’s I-O implications; Novartis’ India job cuts; Moderna’s Asia expansionnews2022-02-18T11:45:45+00:00February 18th, 2022|Fierce Pharma|
Agios’ first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disordernews2022-02-17T21:45:12+00:00February 17th, 2022|Fierce Pharma|
Organon CEO pins high hopes on upcoming Humira biosimilar launchnews2022-02-17T18:05:55+00:00February 17th, 2022|Fierce Pharma|
Bayer hikes Nubeqa’s peak sales to more than €3B on prostate cancer data, teeing up new 3-way battle against Pfizer-Astellas, J&Jnews2022-02-17T17:22:54+00:00February 17th, 2022|Fierce Pharma|
GSK launches trade secrets case against former employee, ordering data and property to be returned ‘in one piece’news2022-02-17T16:02:20+00:00February 17th, 2022|Fierce Pharma|
Teva takes ‘skinny’ label dispute with GlaxoSmithKline to the Supreme Court: reportsnews2022-02-17T14:40:12+00:00February 17th, 2022|Fierce Pharma|
Bristol Myers scores FDA priority review in high-stakes expansion bid for CAR-T drug Breyanzinews2022-02-17T14:34:28+00:00February 17th, 2022|Fierce Pharma|
Eli Lilly, with latest Verzenio nod, teams up with a host of breast cancer groups for new education campaignnews2022-02-17T13:28:13+00:00February 17th, 2022|Fierce Pharma|
Women’s telehealth startup Alloy turns up the heat on men to bring attention to menopause symptomsnews2022-02-17T13:13:04+00:00February 17th, 2022|Fierce Pharma|
